
| 3 min read
John Yu built Kairos Pharma on a simple bet: Cancer drugs don't fail, tumors just learn to outrun them.
| 2 min read
Phase 2b data for EloraTZP suggest the next gains in obesity will come from stacking hormone pathways, and that tolerability may decide who wins.
| 4 min read
Pharma deals, regulatory updates, new treatments and more led the news this week.
| 3 min read
Scientists identified stem cells whose dysregulated calcium signaling drives the degenerative condition, opening the door to novel treatments.News
Cancer Research News
Imagene AI's quantitative pathology and CellCarta's CDx infrastructure offer biopharma sponsors one path from AI biomarker assay to regulatory submission
As 3D cell models advance toward mainstream use, the field must learn to work with biological variability rather than against it.
Editor's Pick
Born to differentiate and heal, mesenchymal stem cells carry great potential for treating a wide spectrum of diseases.
In a journey fraught with heartache and persistence, medical research giants paved the way for successful bone marrow transplantation.
Multimedia
Explore how advances in liquid handling are making automation more accessible, flexible, and practical for modern labs.
Explore how integrated cell-based assays reveal the mechanisms that drive antibody-drug conjugate activity and inform candidate selection.




















